Accessibility Menu
Appili Therapeutics logo

Appili Therapeutics(OTC) APLIF

Market Cap$1.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-99%
5 Year-99%
1 Year-23%
1 Month-17%
$0.01
+2.25%
+0.00Today
Appili Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.012026-08-26
Appili Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.012026-08-19
1 month-17.45%USD 0.012026-07-21
3 month-15.14%USD 0.012026-05-26
Year to date-38.65%USD 0.012025-12-31
1 year-22.72%USD 0.012025-08-26
3 year-75.46%USD 0.042023-08-25
5 year-98.5%USD 0.612021-08-27
Since inception-99.32%USD 1.332020-05-20

Appili Therapeutics Financials at a Glance

Market Cap

$1.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$378.87K

Net Income (TTM)

-CA$4.68M

EPS (TTM)

-$0.03

P/E Ratio

-0.35

Dividend

$0.00

Beta (Volatility)

0.57 (Low)

Price

$0.01

Volume

5

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.01 - $0.03

Estimated Earnings Date

Nov 12, 2026

APLIF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Appili Therapeutics

Appili Therapeutics Inc. is a biopharmaceutical company focused on developing innovative treatments for infectious diseases. The company aims to address unmet medical needs through a diverse portfolio of anti-infective programs, including ATI-1501, ATI-1503, and ATI-1701.

Products and Services
  • Development of novel anti-infective therapies
  • Focus on addressing unmet needs in infectious disease
  • Portfolio includes multiple promising drug candidates
Growth Outlook
  • Recent quarterly revenue of CAD 42,104 shows potential for growth
  • Research and development expenses indicate commitment to innovation
  • Strong gross profit margin of 96.78% highlights product viability
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 1,000,000 reflects market interest
  • Net income for the latest quarter was CAD -1,047,000, indicating ongoing investment
  • Cash and cash equivalents of CAD 40,105 provide operational liquidity
Appili Therapeutics Inc. operates in the biotechnology sector, with a focus on developing treatments for infectious diseases. The company has made significant strides in its research and development efforts, as evidenced by its diverse portfolio of drug candidates. The recent quarterly revenue indicates a growing interest in its products, while the high gross profit margin suggests that the company is on the right track in terms of product viability. Despite facing challenges, such as a net loss in the latest quarter, the ongoing investment in research and development demonstrates a commitment to innovation and long-term growth. The current cash position provides a buffer for operational needs, allowing the company to continue its efforts in bringing new therapies to market. Overall, Appili Therapeutics Inc. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in the area of infectious disease treatment.
AI Generated • Aug 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7

CEO

Don Cilla, MBA

Website

www.appilitherapeutics.com

Headquarters

Halifax, NS B3H 0A8, CA

APLIF Financials

Key Financial Metrics (TTM)

Gross Margin

98.46%

Operating Margin

-1606.24%

Net Income Margin

-1236.07%

Return on Equity

27.40%

Return on Capital

N/A

Return on Assets

-361.50%

Earnings Yield

-2.86%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

132.37M

Volume

5

Avg. Volume

9.17K

Financials (TTM)

Gross Profit

CA$376.29K

Operating Income

-CA$5.87M

EBITDA

-CA$5.86M

Operating Cash Flow

-CA$1.35M

Capital Expenditure

CA$36.99K

Free Cash Flow

-CA$1.32M

Cash & ST Invst.

CA$138.74K

Total Debt

CA$13.33M

Appili Therapeutics Performance Analysis

Appili Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 252,613-77.2%
20242024-03-31CAD 613,426142.8%
20252025-03-31CAD 72,212-88.2%
20262026-03-31CAD 176,673144.7%
Appili Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30N/A
Q32025-12-3110.5%
Q42026-03-31-63.4%
Q12026-06-30180.1%
Appili Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.06-79.5%
20242024-03-31CAD -0.02-62.4%
20252025-03-31CAD -0.02-32.5%
20262026-03-31CAD -0.0259.0%
Appili Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3020.4%
Q32025-12-319.8%
Q42026-03-31-6.8%
Q12026-06-30-62.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

CA$117.94K

N/A

Gross Profit

CA$116.59K

+4489.8%

Gross Margin

98.85%

N/A

Market Cap

$1.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$171.70K

N/A

Employees

7

N/A

Net Income

-CA$1.70M

-36.1%

EBITDA

-CA$1.61M

-121.3%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

CA$138.74K

-87.7%

Total Debt

CA$13.33M

+7.9%

Accounts Receivable

CA$957.26K

+85.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$640.58K

-8.9%

Short Term Debt

CA$12.69M

+9.0%

Return on Assets

-3.62%

N/A

Return on Invested Capital

33.10%

N/A

Free Cash Flow

CA$0.00

+100.0%

Operating Cash Flow

-CA$36.99K

-481.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HESGHealth Sciences Group, Inc.
$0.00+0.00%
AGNPFGrey Matters Health Inc.
$0.36+2.12%
VGLSSB Technology Holdings Inc.
$0.22+0.00%
RGBPRegen BioPharma, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$225.49-0.01%
BITOProShares Trust - ProShares Bitcoin ETF
$10.70-0.01%
INTCIntel
$92.57+0.01%
QNRXQuoin Pharmaceuticals
$6.74+0.31%

Questions About APLIF

What is the current price of Appili Therapeutics?

Appili Therapeutics is trading at $0.01 per share.

What is the 52-week range for Appili Therapeutics?

Over the past 52 weeks, Appili Therapeutics has traded between $0.01 and $0.03.

How much debt does Appili Therapeutics have?

As of the most recent reporting period, Appili Therapeutics reported total debt of CA$9.39M.

How much cash does Appili Therapeutics have on hand?

Appili Therapeutics reported CA$97.75K in cash and cash equivalents in its most recent financial results.

What is Appili Therapeutics’s dividend yield?

Appili Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services